Category

Archives

FGF21 is not required for CR-mediated IGF-1 reduction or cell proliferation inhibition

 

Calorie restriction (CR) is a regimen based on low daily caloric intake without malnutrition. It can decelerate biological aging process, resulting in a delay of many age-related disease and an increase of lifespan. One possible mechanism, related to CR-induced lifespan extension, is down-regulation of insulin-like growth factor-1 (IGF-1) leads to a reduction of cell proliferation rate, then inhibits tumor formation. In addition, it is possible that nutritional deprivation induces up-regulation of fibroblast growth factor 21 (FGF21), leads to a decrease of IGF-1 expression. Thompson et al. design a series of experiments to investigate the changes of growth hormone (GH)-regulated IGF-1 production and the role of FGF21 under CR condition. The article was published on Plos One, recently.

 

In response to moderate CR (25%CR) in adult mice, phosphorylation levels of hepatic signal transducer and activator of transcription 5 (STAT5) were reduced, however, circulating GH and JAK2 levels were unchanged . This result indicates phosphorylated STAT5 may act as a key molecule in the process of CR. On the other hand, FGF21 was not required for the down-regulation of IGF-1 expression level or cell proliferation rates in FGF-knockout mice during moderate CR, although it showed anti-mitotic effects in ad libitum (AL)-fed mice. Due to the well-known glucose-lowering and insulin-sensitizing effects of FGF21, researchers suspect that FGF21 may play other roles in the effects of CR, instead of reducing IGF-1 production and cell proliferation rates.

 

Reference:
Plos One. 2014 Nov 4;9(11):e111418.

Related Products

Cat.No. Product Name Information Publications Customer Product Validation
S1091 Linsitinib (OSI-906) Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3. (134) (6)
S1018 Dovitinib (TKI-258) Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4. (36) (7)

Related Targets